WilmerHale represented the underwriters in the underwritten public offering of 4,944,000 shares of common stock by Disc Medicine, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. Disc received approximately $178.0 million in gross proceeds, excluding underwriting discounts and commissions and other offering-related expenses. The offering priced on June 14, 2017 and closed on June 17, 2024.

The WilmerHale team representing the underwriters included Lisa Firenze, Ryan Brewer, Alex Bloom and Michelle Sidle with assistance from Bruce Manheim on regulatory matters and Barish Ozdamar on intellectual property matters.